scholarly journals Problem-solving in caregiver-counselling (PLiP Study): study protocol of a cluster randomized pragmatic trial

2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Klaus Pfeiffer ◽  
Martin Hautzinger ◽  
Margarete Patak ◽  
Julia Grünwald ◽  
Clemens Becker ◽  
...  
Trials ◽  
2020 ◽  
Vol 21 (1) ◽  
Author(s):  
Bethany M. Kwan ◽  
L. Miriam Dickinson ◽  
Russell E. Glasgow ◽  
Martha Sajatovic ◽  
Mark Gritz ◽  
...  

Trials ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Jan Kottner ◽  
Elisabeth Hahnel ◽  
Monira El Genedy ◽  
Konrad Neumann ◽  
Katrin Balzer

2017 ◽  
Vol 1 (suppl_1) ◽  
pp. 667-667
Author(s):  
K. Pfeiffer ◽  
D. Albrecht ◽  
A. Pendergrass ◽  
C. Becker ◽  
M. Hautzinger

Trials ◽  
2018 ◽  
Vol 19 (1) ◽  
Author(s):  
Megan E. Branda ◽  
Aravind Chandrasekaran ◽  
Marc D. Tumerman ◽  
Nilay D. Shah ◽  
Peter Ward ◽  
...  

Author(s):  
Michele Heisler ◽  
Jennifer Burgess ◽  
Jeffrey Cass ◽  
John F. Chardos ◽  
Alexander B. Guirguis ◽  
...  

Abstract Objective To examine whether diabetes shared medical appointments (SMAs) implemented as part of usual clinical practice in diverse health systems are more effective than usual care in improving and sustaining A1c improvements. Research Design and Methods A multi-site cluster randomized pragmatic trial examining implementation in clinical practice of diabetes SMAs in five Veterans Affairs (VA) health systems was conducted from 2016 to 2020 among 1537 adults with type 2 diabetes and elevated A1cs. Eligible patients were randomly assigned to either: (1) invitation to participate in a series of SMAs totaling 8–9 h; or (2) continuation of usual care. Relative change in A1c (primary outcome) and in systolic blood pressure, insulin starts, statin starts, and anti-hypertensive medication classes (secondary outcomes) were measured as part of usual clinical care at baseline, at 6 months and at 12 months (~7 months after conclusion of the final SMA in four of five sites). We examined outcomes in three samples of SMA participants: all those scheduled for a SMA, those attending at least one SMA, and those attending at least half of SMAs. Results Baseline mean A1c was 9.0%. Participants scheduled for an SMA achieved A1c reductions 0.35% points greater than the control group between baseline and 6-months follow up (p = .001). Those who attended at least one SMA achieved reductions 0.42 % points greater (p < .001), and those who attended at least half of scheduled SMAs achieved reductions 0.53 % points greater (p < .001) than the control group. At 12-month follow-up, the three SMA analysis samples achieved reductions from baseline ranging from 0.16 % points (p = 0.12) to 0.29 % points (p = .06) greater than the control group. Conclusions Diabetes SMAs as implemented in real-life diverse clinical practices improve glycemic control more than usual care immediately after the SMAs, but relative gains are not maintained. Our findings suggest the need for further study of whether a longer term SMA model or other follow-up strategies would sustain relative clinical improvements associated with this intervention. Trial Registration ClinicalTrials.gov ID NCT02132676


Sign in / Sign up

Export Citation Format

Share Document